Literature DB >> 18665853

Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia.

A Rentz1, E Flood, C Altisent, M Bullinger, R Klamroth, R P Garrido, I Scharrer, W Schramm, E Gorina.   

Abstract

Co-morbidities of haemophilia, such as arthropathy and blood-borne infections, can adversely affect the quality of life of adult patients with haemophilia. The purpose of this study was to develop and validate a haemophilia-specific health-related quality of life questionnaire for adults (HAEMO-QoL-A). Subjects with varying severities of haemophilia completed the HAEMO-QoL-A at baseline and 4 weeks. Other assessments included the SF-36 and Health Assessment Questionnaire - Functional Disability Index (HAQ-FDI). Two-hundred and twenty-one participants completed the 41-item HAEMO-QoL-A covering six domains (Physical Functioning, Role Functioning, Worry, Consequences of Bleeding, Emotional Impact and Treatment Concerns) and four independent items. Internal consistency was good-to-excellent (Cronbach's alpha-range: 0.75-0.95). Test-retest reproducibility was good, with intraclass correlation coefficients >0.80 except for the Emotional Impact domain (0.79). Concurrent validity between the HAEMO-QoL-A total and subscale scores and all SF-36 subscale scores were generally good (correlations range: 0.13-0.87). Significant correlations between the HAEMO-QoL-A and the HAQ-FDI ranged from -0.14 to -0.69. There were non-significant correlations with the Treatment Concerns subscale and with the Worry subscale. The HAEMO-QoL-A discriminated significantly between adults with haemophilia by severity and HIV status. The Physical Functioning subscale discriminated between patients receiving prophylactic or on-demand therapy. The HAEMO-QoL-A is a valid and reliable instrument for assessing quality of life in haemophilia patients.

Entities:  

Mesh:

Year:  2008        PMID: 18665853     DOI: 10.1111/j.1365-2516.2008.01812.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  15 in total

1.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

Review 2.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

3.  Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy.

Authors:  Jennifer Quinn; Kathleen A Delaney; Wing Yen Wong; Wolfgang Miesbach; Monika Bullinger
Journal:  Patient Relat Outcome Meas       Date:  2022-07-18

4.  Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.

Authors:  K John Pasi; Michael Laffan; Savita Rangarajan; Tara M Robinson; Nina Mitchell; Will Lester; Emily Symington; Bella Madan; Xinqun Yang; Benjamin Kim; Glenn F Pierce; Wing Yen Wong
Journal:  Haemophilia       Date:  2021-08-11       Impact factor: 4.263

5.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

6.  Patient preference for needleless factor VIII reconstitution device: the Italian experience.

Authors:  Roberto Musso; Rita Santoro; Antonio Coppola; Maura Marcucci; Gianluca Sottilotta; Roberto Targhetta; Ezio Zanon; Massimo Franchini
Journal:  Int J Gen Med       Date:  2010-07-21

7.  Physician trust and depression influence adherence to factor replacement: a single-centre cross-sectional study.

Authors:  D Q Tran; V Barry; A Antun; M Ribeiro; S Stein; C L Kempton
Journal:  Haemophilia       Date:  2016-09-30       Impact factor: 4.287

Review 8.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

9.  Content comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY).

Authors:  Silvia Riva; Monika Bullinger; Edda Amann; Sylvia von Mackensen
Journal:  Health Qual Life Outcomes       Date:  2010-11-25       Impact factor: 3.186

10.  Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Olga Katsarou; Dimitris Niakas
Journal:  Biomed Res Int       Date:  2014-05-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.